Synopsis:- On the surface, Ind-Swift Laboratories’ FY26 standalone net profit of Rs. 25.6 crore looks like a steep fall from the Rs. 256 crore reported in FY25 but almost the entire FY25 profit was driven by a Rs. 216 crore exceptional income from asset disposals. Strip those out and the underlying operating business improved sharply: operating PBT nearly tripled year-on-year to Rs. 61 crore in FY26. Revenue grew 13 percent, and the company now carries a large cash and FD balance of over Rs. 415 crore.
Shares of a Chandigarh-based pharmaceutical API manufacturer came into focus after the board approved its standalone and consolidated audited financial results for FY26, filed on May 28, 2026.
With a market capitalization of Rs. 1,384.7 crore, the shares of Ind-Swift Laboratories were trading at Rs.159.4 per share, up 18.27 percent from its previous close of Rs.134.83 . It is trading at a P/E of 28.34.
FY26 Financial Performance
Standalone revenue from operations grew 13.1 percent year-on-year to Rs. 635.69 crore in FY26 from Rs. 562.17 crore in FY25. Operating profit before exceptional items and tax was Rs. 61.22 crore, up sharply from Rs. 20.94 crore a year ago, a 192 percent improvement that reflects genuine operational recovery in the API business.
After accounting for exceptional items of Rs. 11.01 crore (write-backs net of write-offs), standalone PBT came in at Rs. 50.22 crore. Net profit stood at Rs. 25.56 crore for FY26. Comparing this to FY25’s reported PAT of Rs. 256.09 crore gives the misleading impression of a sharp decline. In reality, the FY25 PAT was almost entirely manufactured by an exceptional income of Rs. 215.88 crore primarily asset disposals and not by operational earnings.
The underlying year-on-year improvement is the more relevant data point. For Q4 FY26, standalone revenue was Rs. 172.71 crore, up 15.5 percent year-on-year, with operating PBT of Rs. 16.87 crore against Rs. 10.27 crore in Q4 FY25.
Merger, Capital Structure, and Interest Income
The FY26 numbers are on a combined entity basis following the NCLT-approved merger of Ind-Swift Limited (ISL) with the company, which became effective from August 8, 2025. The merger was accounted for using the pooling of interest method under Ind AS 103, and a total of 81.25 lakh equity shares were allotted to ISL shareholders. This restructuring means year-on-year comparisons should be treated with caution until a full comparable base year is established post-merger.
The company also completed large-scale warrant conversions during FY26: 1.79 crore warrants were converted into equity shares, with an additional 1.25 lakh shares issued under ESOP 2014. Of the 2.60 crore warrants originally allotted, 65 lakh lapsed unexercised, and the upfront amount received on these was forfeited.
The warrant and ESOP proceeds contributed Rs. 162.98 crore to financing cash flows, which explains the large cash and fixed deposit balance of over Rs. 410.91 crore at year-end. Interest income of Rs. 55.49 crore in FY26 earned on these deposits is now a material contributor to total income, amounting to approximately 8.7 percent of revenue from operations. This is worth monitoring: cash sitting in FDs generating interest is different from cash deployed in the business generating operating returns.
Cash Flow Concern
Despite the improvement in operating profit, standalone cash flow from operations was negative at Rs. 40.19 crore. Trade receivables expanded by Rs. 34.83 crore during the year, inventories by Rs. 35.72 crore, and other current assets by Rs. 49.07 crore indicating that much of the reported operating profit remained tied up in working capital. Negative operating cash flow in a year of revenue growth is a flag that bears watching in subsequent quarters.
Business Overview
Ind-Swift Laboratories Limited, incorporated in 1995 and headquartered in Chandigarh, manufactures active pharmaceutical ingredients (APIs) and intermediates for regulated markets including the US, EU, Japan, Brazil, and other global markets. The company has manufacturing facilities in Mohali (Punjab) and Samba (Jammu & Kashmir), and holds leadership positions in the macrolide antibiotic segment.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
